



International Va'a Federation

Anti-Doping Rules & Regulations



TABLE OF CONTENTS

Topic	Page
Contents	2
Introduction	3
Regulation 1: Principles	3
Regulation 2: Anti-Doping Control	4
Regulation 3: Therapeutic Use Applications	7
Regulation 4: Penalties	9
Regulation 5 : Disciplinary Tribunal	10
Regulation 6 : Disciplinary Appeal Tribunal	11
Regulation 7: Host Country Responsibilities	12
 Appendices	
A Anti-Doping Declaration for All Paddlers	13
B Therapeutic Use Exemption Application	14



INTRODUCTION

The International Va'a Federation (IVF) strictly prohibits the use of banned substances and prohibited methods in va'a racing to ensure that all paddlers compete in a clean and fair environment. IVF's anti-doping rules and regulations are designed to protect paddlers' fundamental right to participate in doping-free competitions while promoting health, fairness, and equality within the sport.

IVF events are conducted in alignment with the World Anti-Doping Agency (WADA) Code. Paddlers are prohibited from using any substances or methods listed on the current WADA Prohibited List. By adhering to the IVF Anti-Doping Rules and Regulations, the IVF ensures that va'a racing maintains integrity, paddler safety, and a level playing field for all competitors worldwide.

Paddlers are responsible for knowing what constitutes an anti-doping rule violation as well as the substances and methods that are included on the current WADA Prohibited List. Every paddler who participates in an IVF-sanctioned event is required to complete the IVF Anti-Doping Declaration Form. Additionally, it is each paddler's responsibility to ensure no prohibited substances enters his or her body. Paddlers are responsible for any prohibited substances or its metabolites or markers found to be present in their test samples. It is not necessary to demonstrate that intent, fault, negligence or knowing use, on the paddler's part, took place in order to establish that an anti-doping rule violation has taken place.

REGULATION 1: PRINCIPLES

1.01 The following categories of conduct are prohibited:

- 1.01.1 The presence of a prohibitive substance or its metabolites or markers in a paddler's test sample or methods appearing on the most recent list of prohibited substances and methods as published by WADA is prohibited. Unless otherwise stipulated in the list, none of the substances belonging to a prohibited category may be used. The use of a prohibited substance shall constitute an infringement of these regulations regardless of the intent of the user.
- 1.01.2 The use of substances that might influence the result of an analysis is also prohibited, and shall be deemed to be an anti-doping rule violation.
- 1.01.3 Assisting or inciting others to use prohibited substances and methods is an infringement of these regulations and will result in a 4-year suspension.
- 1.02 Should an anti-doping test be conducted at any event, it shall be governed by these regulations.
- 1.03 The cost related to anti-doping testing and administration shall be shared equally (50/50) between the IVF and the Host country. This shall not include expenses incurred by a paddler or their legal representative with regards to the required testing of any B Samples.



- 1.04 To the extent of any conflict between the provisions of these regulations for anti-doping and any other statutes of the IVF, these regulations for anti-doping shall prevail.

REGULATION 2: ANTI-DOPING CONTROL

- 2.01 Any paddler who is participating in an IVF-sanctioned World Competition (Sprint or Distance) and is 18-years-old or older, may be subject to in-competition testing. The IVF may require any in-competition paddler to submit to one or more tests. The IVF will decide on the methods of selection of paddlers for testing.
- 2.02 For those who are subject to testing, failure to submit to an anti-doping test, at the place and time required, shall be considered an offence under these regulations and the paddler will be deemed to have recorded a positive result from a test. In the case of the failure to submit to an anti-doping test, the paddler will be suspended from participating in any IVF-sanctioned event for four (4) years from the date of the offense.
- 2.03 The IVF, in conjunction with a WADA-compliant agency, shall be responsible for the organization of the tests. The IVF and WADA-compliant agency shall ensure that all personnel, all necessary facilities and all equipment required are present so that the tests may proceed in accordance with these regulations.
- 2.04 All doping control shall be under the supervision of the IVF Medical Committee, which shall be established by the IVF. The IVF Medical Committee shall include:
- i Qualified, registered medical practitioners, and
 - ii When possible, an IVF Board Member with experience and/or expertise in the activities of the committee.
- 2.05 The IVF, in conjunction with the Host country, shall ensure that the Doping Control Station (DCS) is a secure, private facility designated for the collection of urine samples from paddlers for anti-doping testing. Ensure that the DCS is a strictly limited-access area, located near the competition venue's finish line. Additionally, it must include:
- i Privacy and Security: The area must be inaccessible to the public, media and spectators. It cannot be used as a public restroom, office or team locker room.
 - ii Waiting Area: A room where athletes wait to provide samples, often stocked with water in sealed bottles to help with hydration.
 - iii Processing Room: A private space where the athlete, their representative, and the Doping Control Officer (DCO) complete the sampling paperwork and seal the specimen.
 - iv Toilet Area: Private toilets specifically for sample provision, where a same-gender official must directly witness the urine leaving the body to prevent tampering.
 - v Clearly posted signs.



2.06 The following provisions shall apply in respect to selection, notification and reporting for testing:

2.06.1 Selection:

- i The paddler selected for testing will be notified by a Doping Control Officer (DCO) and an IVF Medical Committee representative.
- ii The selection should happen immediately following the completion of the paddler's event.
- iii The paddler's Area Coordinator shall be notified of the paddler's selection for testing.
- iv When appropriate, an interpreter may accompany the DCO at the time of notification and throughout the process.

2.06.2 Notification:

- i Notice of a test shall be given to the paddler as soon as possible after the completion of the event.
- ii The delivery of this notice shall be carried out as discreetly as possible.
- iii The DCO will inform the paddler of their rights and responsibilities.
- iv The paddler shall acknowledge receipt of the notification.

2.06.3 Reporting:

- i The paddler must report immediately to the Doping Control Station (DCS).
- ii The paddler must remain in the direct sight of the DCO or chaperone until the process is complete.

2.07 Delays in Testing: Paddlers notified by the DCO for testing must report immediately to the DCS, but can request a delay for valid reasons.

2.07.1 Valid reasons for a delay in testing include:

- i Attending a medal ceremony;
- ii Competing in further heats or another race prior to producing a sample;
- ii Medical treatment, and
- iv Scheduled media commitments.

2.07.2 Protocol for Delayed Testing:

- i The paddler must notify the DCO/chaperone of the valid reason for delay;
- ii The DCO and/or IVF Medical Committee official must approve the delay;
- iii Supervision: From the moment of notification until the sample is provided, the paddler will be under observation by a chaperone or DCO to ensure the integrity of the test.
- iv It is the paddler's responsibility to manage their schedule while under observation and to report immediately to the DCS once the reason for delay is completed.
- v Failure to Comply: If the paddler leaves the view of the DCO or chaperone, or fails to report after the valid delay, may face a "failure to comply" charge, which will result in a 4-year suspension.



- 2.08 Upon selection for testing, the paddler must show their identification and declare, in writing, any recent blood transfusions or other infusions, as well as, any medications and other substances including vitamins, dietary supplements and the like.
- 2.09 If a Therapeutic Use Exemption (TUE) has been approved for the current competition, the paddler must declare the medication and/or prohibited substance on the Doping Control Form at the time of testing and clearly indicate that a TUE has been granted.
- 2.10 In addition to the paddler only the following persons may be present in the Doping Control Station (DCS):
- i A designated member of the IVF Medical Committee,
 - ii WADA-compliant Doping Control Officers,
 - iii The paddler's Area Coordinator,
 - iv A gender appropriate chaperone,
 - v An interpreter (when required).
- 2.11 The procedure for the collection of test samples shall be as described below:
- 2.11.1 At the time of testing, the paddler shall provide, under the direct and continuous supervision of the DCO(s), not less than 80 mL of urine. The specimen shall be divided, by the paddler, into two substantially equal aliquots. Each aliquot shall be uniquely coded to ensure traceability and clear differentiation from all other specimens and from one another. The primary aliquot shall be designated and labelled "Sample A." The secondary aliquot shall be designated and labelled "B Sample" and retained for confirmatory analysis, if necessary.
- 2.11.2 Only the selected paddler shall be present in the examination room when urine is collected. The DCO(s) shall also be present for the duration of the procedure.
- 2.11.3 The paddler must:
- i Select the containers for the samples from the containers available, and
 - ii Personally verify the sealing and identification of the containers.
- 2.11.4 Written confirmation must be obtained from both the paddler and the DCO stating that the prescribed guidelines have been substantially followed. A copy of this confirmation must be provided to the paddler. Any deviations from the procedures must be documented on the confirmation form.
- 2.11.5 The paddler shall be handed, upon completing the test, a receipt with the details of the container coding, date and time taken, and examining officer endorsed thereon. This receipt may be incorporated in the written confirmation referred to in 2.10.4 above. The DCO, on behalf of the IVF Medical Committee, will restrict access to samples at the Doping Control Station (DCS) and during transportation and in the laboratory. Thereby, maintaining proper chain of custody of the testing samples.



- 2.12 The sample(s) shall be forwarded without delay to a laboratory accredited by an agency affiliated with or compliant with WADA for analysis.
- 2.13 If the analysis of the A Sample indicates the presence of a prohibited substance, the IVF shall promptly notify the paddler's governing body in writing. The paddler shall notify the IVF within seven (7) days of such notification whether the paddler requests analysis of B Sample.

Upon receipt of the paddler's request, B Sample shall remain secured at the laboratory that conducted the A Sample analysis and shall be analyzed as soon as practicable. The date and time of the B Sample analysis shall be promptly communicated in writing to the paddler's governing body.

The cost of the B Sample analysis shall be borne by the paddler.

When the result of the B Sample is received, the IVF shall promptly notify paddler's governing body in writing as set out in 2.15 below. The IVF will revise any race results accordingly.

- 2.14 The IVF shall take all reasonable steps to ensure that all details concerning anti-doping testing are kept confidential unless the paddler is found guilty for use of a prohibited substances, methods or markers and advised accordingly under these regulations.
- 2.15 With respect to an alleged infringement of Regulations 1.01.2 and 1.01.3, which fall within the scope of Regulation 1.10.1, the IVF Medical Committee shall notify the paddler concerned of details of the alleged infringement. The IVF Medical Committee shall review the test results and determine the penalties as defined in Regulation 4.
- 2.16 In all its deliberations and determinations, the IVF TUE Committee will use the WADA list of prohibitive and restrictive substances and prohibited methods.

REGULATION 3: THERAPEUTIC USE EXEMPTION

- 3.01 The IVF has insured that there is a process in place for any paddler who chooses to enter an IVF sanctioned World competition, whereby, adult paddlers with documented medical conditions requiring the use of a prohibited substance or a prohibited method may request a Therapeutic Use Exception (TUE) for the duration of the event. A TUE allows a paddler to use a prohibited substance or method for legitimate medical reasons without violating IVF anti-doping rules and regulations.
- 3.02 TUE request shall be evaluated in accordance with the WADA/IVF International Standard for Therapeutic Use Exemptions (ISTUE).
- 3.03 The criteria used to determine the granting of a therapeutic use exemption are:
- i The paddler would experience significant health problems without taking the prohibited substance or method;



- ii The therapeutic use of the substance would not produce significant enhancement of performance, and
 - iii There is no reasonable therapeutic alternative to the use of the otherwise prohibited substance or method.
- 3.04 The IVF Therapeutic Use Exemption Committee (TUEC) shall consist of: a chairperson who is a member of the IVF Medical Committee; a licensed medical physician, and other healthcare professionals, such as pharmacists. Additionally, when necessary, appropriate medical specialists may be consulted.
- 3.05 The TUEC is responsible for reviewing and determining all TUE applications. Applications must be submitted to the TUEC via email through the Area Coordinator for the paddler's country/area governing body, no later than 70 days prior to the first day of competition.
- 3.06 If paddler's TUE is approved, the paddler may continue treatment, with the approval to compete, after receiving the authorization notice from the IVF Medical Committee
- 3.07 Therapeutic Use Exemptions (TUEs) are granted for a specific medication at a defined dosage. They are valid only for a specified period and expire at the conclusion of the event. The paddler must comply with all treatment conditions outlined in the TUE application. Once a TUE has been approved by the IVF Medical Committee's TUEC, the paddler will be notified in writing via email by the appropriate Area Coordinator of the committee's decision.
- 3.09 If a paddler, who has been granted a TUE, is randomly selected for testing and the approved prohibited substance is detected during the analysis of A Sample, the TUEC will verify that the TUE was in effect for the duration of the competition, and that the results of the analysis are consistent with the TUE granted (nature of substance, route of administration, dose, time-frame of administration, etc.). If the review proves satisfactory, the result of the test will be recorded as negative.
- 3.10 To be granted a TUE, a paddler's application must be thoroughly completed and signed by the treating doctor and paddler and include:
- i Official medical records or chart notes supporting the diagnosis.
 - ii Documentation showing that the condition requires treatment with a prohibited substance or method.
 - ii Specific details of:
 - a) The substance(s) being prescribed;
 - b) The dosage;
 - c) The route/method of administration (e.g., oral, injection, inhalation);
 - d) The duration of treatment.

Failure to do so will result in a rejected TUE application.



- 3.11 The TUEC will not accept TUEs where the paddler is identified as their own treating physician.
- 3.12 Emergency Therapeutic Use Exemptions: An Emergency TUE application may be submitted after the deadline, but before the beginning of a competition/event if there is insufficient time, opportunity or other exceptional circumstances that prevented the paddler to submit a standard TUE application.
- 3.12.1 Emergency TUEs are not automatically accepted or granted. They require the same review process, and level of medical documentation and authorizing signatures as a standard TUE.
- 3.12.2 Emergency TUEs may be considered by the TUEC under the following circumstances:
- i An emergency or urgent medical condition occurred after the 70-day deadline required for a standard TUE application, or
 - ii If a medical condition was diagnosed days before the 70-day deadline required for a standard TUE application, but there was not sufficient time to submit one.
- 3.13 Retroactive Therapeutic Use Exemptions: A Retroactive TUE is an application submitted to the Therapeutic Use Exemption Committee (TUEC) after the conclusion of the relevant competition or event. Retroactive TUEs are not automatically granted and are considered only in rare and exceptional circumstances, with the same review process, and level of medical documentation and authorizing signatures as a standard TUE.
- Retroactive TUE applications may be reviewed in the following situations:
- i Emergency Medical Treatment, where a paddler required urgent medical treatment during a competition or event involving the use of a prohibited substance or method, and it was not possible to submit a TUE application until after to the competition/event.
 - ii Exceptional Circumstances, where, due to specific and unforeseen circumstances, considerations of fairness and equity justify the retroactive approval of a TUE.
- 3.14 The IVF will not review or approve Therapeutic Use Exemption (TUE) applications submitted by physicians acting as both the treating practitioner and the applicant.

REGULATION 4: PENALTIES

- 4.01 Where a paddler has infringed Regulation 1.01 the paddler shall be automatically disqualified from any competition under the IVF provisions. Such disqualification will take effect (subject to Regulation 3.02) from the beginning of the competition/event in which the paddler tested positive and will to continue until such time as the IVF reinstates the paddler. Unless otherwise stated, the following penalties will be enforced:



The IVF shall determine the period of disqualification to be for:

Prohibited substance and or method: In-Competition

- i 1st offense: 1 year
- ii 2nd offense: 2 years
- iii 3rd offense: 6 years

Prohibited substance and/or method: Prohibited at all times

- i 1st offense: 2 years
- ii 2nd offense: 4 years
- iii 3rd offense: 6 years

4.02 If the result of an A Sample is positive, the paddler shall be suspended from competition provided that the IVF shall first give the paddler the opportunity to be heard. Where a paddler's test is positive in an A Sample, the paddler's governing body will be informed.

4.03 Where a paddler has infringed either of regulations 1.01.2 or 1.01.3 of these regulations, that paddler shall be liable to disqualification in the same manner as if the paddler had infringed regulation 1.01.1 with the disqualification to take effect from the date the IVF Medical Committee determines the infringement to have taken place.

The IVF shall notify its decision concerning the infringement and penalties to the paddler and the paddler's area governing body, via his/her Area Coordinator, upon determination.

REGULATION 5: Disciplinary Tribunal

5.01 Upon notification to the IVF Medical Committee, from the accredited WADA lab or WADA directly, of a positive A Sample test, a Disciplinary Tribunal will be established to review the results and the circumstances surrounding the paddler's test results.

The Tribunal shall be created by the IVF Medical Committee and consist of at least three members with at least one of the following backgrounds:

- i A member of the IVF Medical Committee;
- ii An medical practitioner with experience in paddling and/or sports medicine and having a full knowledge of the classes of pharmacological agents and methods;
- iii IVF Board member or someone familiar with va'a racing;
- iv Other individual the Medical Committee deems a benefit to the proceedings.

The Tribunal may retain legal counsel for review of all relevant documents related to the actions of the Tribunal.

5.02 The Tribunal has the authority to hear and determine all matters arising from any matter, which is referred to it by the IVF Medical Committee in accordance with these regulations. In particular, it has the authority to impose the penalties provided for in these regulations.



- 5.03 No proceedings heard by the Disciplinary Tribunal shall be held invalid by reason only of any defect; irregularity, omission or other technicality provided there has been no miscarriage of justice.
- 5.04 Subject to these Regulations, a paddler who receives notice from the IVF Medical Committee in relation to a positive test result shall appear before the Disciplinary Tribunal at a venue, date and time as determined by the Tribunal. The paddler may waive their right to appear. Interpreters may be present at Tribunal hearings where the Tribunal considers it necessary or desirable.
- 5.05 For the purposes of the Regulations, all of the paddler's costs associated with any proceedings before the Tribunal shall be borne by the paddler.
- 5.06 Autonomy of the Tribunal constituted under these Regulations shall exercise its functions independently of both the IVF and its area governing bodies. The Tribunal shall be fully autonomous, and any decision it makes shall be binding on the IVF and its area governing bodies, none of whom shall have the power to affirm, revoke or alter any decision.
- 5.07 At the conclusion of the hearing by the Tribunal, a written report shall be prepared and forwarded to the Chairperson of the IVF Medical Committee detailing comprehensively the relevant circumstances to the case, the outcome of the hearings and any penalties imposed by the Tribunal and making any recommendations it deems appropriate.
- 5.08 Six weeks shall be the maximum duration in which any hearing and final outcome shall be completed. The period shall commence from the time the paddler is informed of a positive result.

REGULATION 6: Disciplinary Appeal Tribunal

- 6.01 Provision is made for a Disciplinary Appeal Tribunal (DAT) to be established when an appeal of a decision of the Disciplinary Tribunal is required.
- 6.02 This Disciplinary Appeal Tribunal (DAT) shall consist of three new members as defined in Regulation 4(4.0.1) Disciplinary Tribunal. The DAT shall have the power to hear and determine appeals from any decision of the Disciplinary Tribunal.
- 6.03 Where any question of fact arises on an appeal before the Disciplinary Appeal Tribunal, it shall be determined by reference to the recording of proceedings before the Disciplinary Tribunal. The Disciplinary Appeal Tribunal may rehear in whole or any part of the evidence given before the Disciplinary Tribunal, as it considers appropriate.
- 6.04 The Disciplinary Appeal Tribunal shall have the full discretionary power to hear and receive such further evidence on an appeal as it thinks fit provided it is established that such evidence was not, on reasonable inquiry, available at the time of the original hearing. The Disciplinary Appeal Tribunal shall be entitled to receive such evidence as



it thinks fit notwithstanding that the evidence may not be legally admissible in a court of competent jurisdiction.

- 6.05 In exercising its jurisdiction, the Disciplinary Appeal Tribunal shall have the power to overturn, suspend, vary the penalty imposed, subject to the mandatory nature of any penalties provided for in Regulation 4.
- 6.06 No proceedings heard by the Disciplinary Appeal Tribunal shall be held invalid by reason only of any defect; irregularity, omission or other technicality provided there has been no miscarriage of justice.
- 6.07 The venue for such a rehearing shall be determined by the Disciplinary Appeal Tribunal, which shall state the venue, date and time in which the rehearing will take place. Interpreters may be present at Appeal Tribunal hearings where the Appeal Tribunal considers it necessary or desirable.
- 6.08 All of the paddler's costs associated with any proceedings before the Disciplinary Appeals Tribunal shall be borne by the paddler.
- 6.09 The Disciplinary Appeal Tribunal shall exercise its function independently of the IVF and its area governing bodies and shall be fully autonomous and in particular any decision it makes shall be binding on the IVF and its area governing bodies none of whom shall have the power to affirm, revoke or alter any decision.

REGULATION 7: Host Country Responsibilities

There shall be a host medical committee for any IVF sanctioned event as arranged between the IVF Medical Committee and the Host organizing committee.

7.01 The responsibilities of the Host include:

- i. Working with the IVF Medical Committee on all aspect of anti-doping enforcement.
- ii. Assist in making arrangements for doping control with regional WADA affiliated anti-doping body.
- iii. Establishing and maintaining a staffed emergency medical care facility for the paddlers and their officials throughout the event – from practice days to event finish.
- iv. Maintaining medical confidentiality.
- v. Understanding and complying with the site obligations for anti-doping control and the provision for the Doping Control Station (DCS).
- vi. Providing security for the DCS.
- vii. Producing a report for the IVF Medical Committee providing a full accounting of the services rendered during the event, as well as any recommendations to improve future events.



INTERNATIONAL VA'A FEDERATION (IVF) Therapeutic Use Exemption (TUE) Application Form

Please complete all sections in capital letters or typing. Athlete to complete sections 1, 2, 3 and 7; Physician to complete sections 4, 5 and 6. Illegible or incomplete applications will be returned and will need to be re-submitted in legible and complete form.

1. Paddler/Athlete Information

Last Name: _____	First Name(s): _____
Female: <input type="checkbox"/>	Male: <input type="checkbox"/>
	Date of Birth: _____ <i>(dd/mm/yyyy)</i>
Address: _____	
City: _____	Country: _____
Postcode: _____	Telephone: _____ <i>(With International Code)</i>
Email: _____	
Sport: <u>VA'A (Outrigger Canoe)</u> _____	

2. Previous Applications

Have you submitted any previous TUE application(s) to the IVF for the same condition?

Yes No

For which substance(s) or method(s)? _____

When? _____

Decision: Approved Not approved

3. Emergency and Retroactive Applications

Is this an emergency application? (Requested after the IVF deadline)

Yes No

If yes, on what date was the treatment started? _____

Do any of the following exceptions apply?

- (a) - You required emergency or urgent treatment of a medical condition.
- (b) - There was insufficient time, opportunity or other exceptional circumstances that prevented you from submitting the TUE application, or having it evaluated, before the deadline.
- Please explain (if necessary, attach further documents)

Retroactive Applications:

In rare and exceptional circumstances notwithstanding an Athlete may apply for and be granted retroactive approval for their TUE if, considering the purpose of the Code, it would be manifestly unfair not to grant a retroactive TUE.

In order to apply for retroactive TUE consideration, please include a full reasoning and attach all necessary supporting documentation.

Treating Physician to Complete Sections 4, 5 and 6.

4. Medical Information (please attach relevant medical documentation)

Diagnosis (Additionally, please use the latest ICD classification- ICD-10):

5. Medication Details

Prohibited Substance(s)/Method(s) <u>Generic name(s)</u>	Dosage	Route of Administration	Frequency	Start and Duration of Treatment
1.				
2.				
3.				
4.				
5.				
6.				

****To complete this TUE application, you must attach:**

- Official medical records or chart notes supporting the diagnosis, including the results of examinations, laboratory tests and imaging studies.
- Documentation showing that the condition requires treatment with the prohibited substances or methods that you list above.

6. Medical Practitioner's Declaration

I certify that the information in sections 4, 5 and 6 is accurate. I acknowledge and agree that my personal information may be used by IVF and/or Anti-Doping Organization(s) (ADO) to contact me regarding this TUE application, to verify the professional assessment in connection with the TUE process, or in connection with Anti-Doping Rule Violation investigations or proceedings. for more details). Please know that this patient/paddler's medical information will be stored for review purposed in a secure virtual site. It will be reviewed by healthcare professionals and the patient/paddler's privacy will be maintained at all times. To ensure confidentiality, this document will be destroyed at the end of the anti-doping testing process for this event – in approximately 9 months.

Name: _____

Medical specialty: _____

License number: _____ License body: _____

Address: _____

City: _____ Country: _____

Postcode: _____

Telephone: _____ Fax: _____

(With International Code)

Email: _____

Signature of Medical Practitioner: _____ Date: _____

(dd/mm/yyyy)

7. Paddler/Athlete's Declaration

I, _____, certify that the information set out at sections 1, 2, 3 and 7 is accurate and complete.

I authorize my physician(s) to release the medical information and records that they deem necessary to evaluate the merits of my TUE application to the following recipients: the IVF Medical Committee, who is responsible for making a decision to grant, reject, or recognize my TUE; the In-Competition testing management entity, should I be random selected for testing; the physicians and healthcare providers who are members of relevant TUE Committee (TUEC) who may need to review my application in accordance with the World Anti-Doping Code and International Standards; and, if needed to assess my application, other independent medical, scientific or legal experts.

I have read and understood the TUE Privacy Notice explaining how my personal information will be processed in connection with my TUE application, and I accept its terms.

Paddler/Athlete's signature: _____ Date: _____
(dd/mm/yyyy)

Guardian's signature: _____ Date: _____
(dd/mm/yyyy)

(If the Athlete has an impairment preventing them from signing this form, a guardian shall sign on behalf of the Athlete).

TUE Privacy Notice

This Notice describes the personal information processing that will occur in connection with your submission of a TUE Application.

TYPES OF PERSONAL INFORMATION (PI)

- The information provided by you or your physician(s) on the TUE Application Form (including your name, date of birth, contact details, sport and discipline, the diagnosis, medication, and treatment relevant to your application);
- Supporting medical information and records provided by you or your physician(s); and
- Assessments and decisions on your TUE application by the IVF and their TUE Committee and other TUE experts, including communications with you and your physician(s), relevant support personnel regarding your application.

PURPOSES & USE

Your PI will be used in order to process and evaluate the merits of your TUE application in accordance with the International Standard for Therapeutic Use Exemptions. In some instances, it could be used for other purposes in accordance with the World Anti-Doping Code (Code), the International Standards, and the anti-doping rules of IVF which as the authority to test you. This includes:

- Results management, in the event of an adverse or atypical finding based on your sample(s); and
- In very rare cases, investigations, or related procedures in the context of a suspected Anti-Doping Rule Violation (ADRV).

TYPES OF RECIPIENTS

Your PI, including your medical or health information and records, may be shared with the following:

- The IVF Medical TUE Committee (TUEC) for making a decision to grant, reject, or recognize your TUE, as well as their delegated third parties (if any). The decision to grant or deny your TUE application will also be made available by the IVF with onsite testing authority and/or results management authority over you;
- Your Area Coordinator, as the courier of your PI to the IVF Medical Committee;
- Members of the IVF Committees: and
- Other independent medical, scientific or legal experts, if needed.

Note that due to the sensitivity of PI TUE information, only a limited number of the IVF Medical Committee receive access to your application. The IVF must handle your PI in accordance with the International Standard for the Protection of Privacy and Personal Information (ISPPPI).

RETENTION

Your PI and TUE determination decisions will be retained for 2 years. TUE application forms and supplementary medical information will be retained for 12 months from the expiry of the TUE. Incomplete TUE applications will be retained for 12 months.

CONTACT

Should you have any questions please contact your Area Coordinator and/or the IVF Medical Committee at medical@ivfiv.org